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The present study anticipates the development of novel antioxidant, antimicrobial and antitubercular drugs by using the 
indole scaffold. Novel indole derivatives, (4a-c), (5a-c) and (6a-i) have been prepared. The structures of all these unknown 
compounds have been confirmed with the help of elemental analysis, IR, 1H & 13C NMR and mass spectral data. All these 
previously unknown synthesized compounds screened for their antioxidant, antimicrobial and antitubercular activities. 
Compound 5a exhibited good RSA 76.58 %, IC50 value <25 µg/mL. Compound 5a exhibited higher absorbance 0.691nm, at 
concentration 100 µg/mL. Compound 6a showed good metal chelating activity (64.10 %) at a concentration 100 µg/mL. 
Compound 6a showed potent activity against S. aureus and P. aeruginosa. Compounds 4a and 5a showed promising 
antitubercular activity MIC 6.25 µg/mL. Compound 6a showed excellent activity (MIC= 3.125 µg/mL) against 
M. tuberculosis H37Rv, than the standards pyrazinamide (MIC= 3.125) and Streptomycin (6.25 µg/mL).
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Antioxidants are playing a vital role because of their 
involvement in biological and industrial processes. In 
general, compounds with antioxidant activity have 
been found to posses anti-cardiovascular, anti-
inflammatory and anticancer1-3 activities. Reactive 
oxygen species (ROS) and antituberculosis4. Free 
radicals are considered to be implicated in a variety of 
pathological events, such as cancer and aging agents5-7.  
Indole derivatives constitute an important class of 
therapeutic agents in medicinal chemistry such as 
antimicrobial8, antioxidant9, antiviral10, anti-HIV, 
antimalarial11 and dihydropyrimidine derivatives are 
widely used for the variety of pharmacological 
activities12,13, antitubercular14, antitumor15, antiepileptic16, 
antimalarial17, antiviral18, anti-inflammatory19, 
analgesic20 and antimicrobial21 activity.  
The treatment of infectious diseases still remains an 
important and challenging problem because of a 
combination of factors including emerging infectious 
diseases and the increasing number of multi-drug 
resistant microbial pathogens. In spite of a large 
number of antibiotics and chemotherapeutics available 
for medicinal use, at the same time the emergence of 
resistance developed against old and new antibiotics in 
the last decades revealed a substantial need for new 
classes of antimicrobial agents. There is really 
perceived need for the discovery of new compounds 
endowed with antimicrobial activity, possibly acting 
through mechanisms of action, which are distinct from 
those of well-known classes of antibacterial agents to 
which many clinically relevant pathogens are now 
resistant22.  
There are many marketed drugs containing the 
1,2,4-triazole group e.g., triazolam, alprazolam, 
etizolam and furacyclin. From the literature22, it may 
be predicted that 1,2,4-triazole moiety represents 
important pharmacophore and play a vital role in 
medicinal agents. A degree of respectability has been 
bestowed upon 1,2,4-triazole derivatives due to their 
wide range of biological activities such as 
antibacterial23, antifungal24, antitubercular25, 
anticancer26 anti-tumor27 activity. 
In view of the above findings and in continuation 
of our research on the synthesis of biologically 
active molecules28-32 in present investigation we 
report the synthesis, antioxidant, antimicrobial and 
antitubercular activities of novel indole derivatives. In 
the design of new drugs, the combination of different 
pharmacophores frame may lead to compounds with 
interesting biological profile. 




Results and Discussion 
 
Chemistry 
A mixture of 2-cyanoacetohydrazide (1), 2, 5-
disbsituted indol-3-carboxaldehyde (2), ethyl-2-
cyanoacetate (3) in ethanol using catalytic amount of 
acetic acid under reflux temperature to afforded ethyl 
1, 2-diamino-4-(5-substituted-2-phenyl-1H-indo-3-
yl)-5-cyano-6-oxo-1,6-dihydropyridin-3-carboxylates 
(4a-c). Compounds 4a-c react with triethyl-
orthoformate under reflux condition to gave Ethyl 7-
(5-sunstituted-2-phenyl-1H-indo-3-yl)-5-cyano-6-oxo-
1,5-dihydro[1,2,4]triazol[1,5]pyridin-3-carboxylates 
(5a-c). Compounds 5a-c hydrazinolysis in boiling 
ethanol afforded the Ethyl 7-(5-chloro-2-phenyl-1H-
indo-3-yl)-5-cyano-6-oxo-1,5-dihydro[1,2,4]triazol 
[1,5]pyridin-8-carbohydrazides (6a-c). Structure of all 
the newly synthesized compounds have been 
accomplished on the basis of elemental analyses and 
spectral techniques like IR, 1H NMR, 13C NMR and 
Mass spectroscopy. The detailed synthetic strategy is 
outlined in (Scheme I). Analytical and spectral data of 






1,1-Diphenyl-2-picryl hydrazyl (DPPH) radical scavenging 
activity (RSA) 
Numbers of methods are available for the 
determination of free radical scavenging activity (RSA) 
but the assay employing the stable DPPH. has received 
much attention owing to its ease of use and 
convenience. This assay is the most widely used  
in vitro test to asses’ free radical scavenging capacities 
of test compounds. The RSA of synthesized 
compounds was carried out at 25, 50, 75 and 100 µg/mL 
concentrations in methanol using DPPH method. All the 
analyses results performed on three replicate and the 
results were averaged. Results are expressed as 
percentage decrease with respect to the control values.  
The results are illustrated in the Table I. 
Compounds 4a, 5a, 6a, 4c, 5c & 6c, showed good 
RSA (76.58, 73.82, 74.65, 70.24, 75.20 & 71.90%) at 
concentration 100 µg/mL. The best result was 
obtained by compound 5a (76.58 %, IsC50 value <25 
µg/ml) when compared to standards BHA (92.28 %), 
TBHQ (91.46 %) and AA (94.21 %). This higher 
RSA may be attributed to the presence of two amino 
group and electronegative chlorine group present in it, 
which may be responsible for stabilization of free 
radical formed after donating a hydrogen atom to 
DPPH free radical. However, none of the compounds 
exhibited better activity than the standards. 
 
Ferric ions (Fe3+) reducing antioxidant power 
(FRAP) 
The reductive capacities of synthesized compounds 
were assessed by the extent of conversion of 
Fe3+/ferricyanide complex to the Fe2+/ferrous form. 
The reductive power of the compounds was observed 
at different concentrations and results were compared 
with standards BHA, TBHQ and AA. The reducing 
ability result was given in the Table II.  
Compounds 4a, 5a, 5b, 5c and 6a reduced metal 
ion complexes to their lower oxidation state or take 
part in electron transfer reaction. In other words, these 
compounds showed the ability of electron donor to 
scavenge free radicals. The rest of the compounds 
showed lower absorbance as compared to the 
 
Scheme I ― Synthetic approach for the preparation of the
compounds (4-6a-c) 
Table I ― DPPH radical scavenging activity of compounds (4-6) 
Concentrations 









4a 60.05 62.80 64.73 76.58 < 25 
4b 52.34 55.64 60.05 64.18 < 25 
4c 58.12 61.14 66.66 70.24 < 25 
5a 64.46 65.84 68.59 73.82 < 25 
5b 60.33 63.63 68.87 72.17 < 25 
5c 61.98 64.73 68.31 75.20 < 25 
6a 56.47 61.98 68.04 74.65 < 25 
6b 54.26 60.33 62.25 68.04 < 25 
6c 57.85 60.05 63.90 71.90 < 25 
BHA 85.95 88.98 90.90 92.28 < 25 
TBHQ 86.50 87.87 89.25 91.46 < 25 
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standards. The best result was obtained by compound 
5a higher absorbance 0.691nm, at concentration 100 
µg/ml when compared to standards BHA, TBHQ and 
AA. The higher the absorbance of the compounds 
indicated greater reducing power. 
 
Ferrous (Fe2+) metal ion chelating activity 
Among the transition metals, iron is known as the 
most important lipid oxidation pro-oxidant due to its 
high reactivity. The effective ferrous ions chelators 
may also afford protection against oxidative  
damage by removing iron (Fe2+) that may otherwise 
participate in hydroxyl radical generating Fenton type 
reactions33.  
 
Fe2+ + H2O2 → Fe
3+ +OH- + OH.  
 
Ferric (Fe3+) ions also produce radical from 
peroxides although the rate is tenfold less than that of 
ferrous (Fe2+) ion34. Ferrous ion is the pro-oxidant 
among the various species of metal ions35. 
Minimizing ferrous (Fe2+) ion may afford protection 
against oxidative damage by inhibiting production of 
reactive oxygen species (ROS) and lipid production. 
Ferrozine can quantitatively form complexes with 
ferrous ions in this method. In the presence of 
chelating agents the complex formation is disrupted 
resulting in a decrease in red color of the complex. 
Measurement of color reduction therefore allows 
estimating the metal chelating activity of the co-
existing chelators. Lower absorbance indicates higher 
metal chelating activity. The chelating effects of 
ferrous ions (Fe2+) with test compounds were 
determined using standards BHA, TBHQ and AA. 
In this assay, synthesized compounds interfered 
with the formation of ferrous and ferrozine complex. 
From the Table III it was concluded that, compounds 
4a, 5a, 6a, 4c, 5c and 6c exhibited (68.42, 64.70, 
74.10, 66.27, 61.91 and 62.30 %, IC50 value <25 
µg/ml), respectively, these compounds exhibited good 




Antimicrobial activity results (Table IV) the MIC 
value it is clear that most the tested compounds were 
active in the concentration range of 62.5–250 µg/mL 
which is comparatively more or equipotent than the 
standards gentamycicn and fluconazole. Antibacterial 
activity of screened samples, compound 4a showed 
potent activity (62.5 µg/mL) against Escherichia coli 
(MTCC-723), 5a showed potent activity (62.5 µg/mL) 
against Pseudomonas aeruginosa  
(MTCC-1688) and 6a showed potent activity (62.5 
µg/mL) against Staphylococcus aureus (ATCC-
29513) and Pseudomonas aeruginosa (MTCC-1688), 
this potent activity may be due to presence of chlorine 
atom at C-5 position of indole system. Remaining all 
the tested compounds exhibited equipotent or less 
potent activity than the standard. Compounds 4a, 5a 
and 6a exhibited equipotent activity against all the 
above four microorganisms when compare with the 
standard. Whereas, Rest of the compounds in the 
series exhibited moderate to less activity. 
Antifungal activity screening results revealed that 
the compounds 4a and 5a showed potent activity 
(62.5 µg/mL) against Aspergillus niger (MTCC-281), 
6a showed potent activity (62.5 µg/mL) against 
Aspergillus oryzae (MTCC-3567T), Aspergillus flavus 
(MTCC-1973) and Aspergillus terreus (MTCC-1782), 
this potent activityt may be due to presence of 
Table II ― Ferric ions (Fe+3) activity of compounds 4-6 









4a 0.255 0.393 0.519 0.621 
4b 0.219 0.285 0.348 0.465 
4c 0.268 0.299 0.345 0.485 
4a 0.210 0.391 0.573 0.691 
4b 0.221 0.278 0.394 0.534 
4c 0.296 0.288 0.469 0.497 
5a 0.277 0.398 0.478 0.686 
5b 0.263 0.379 0.513 0.516 
5c 0.190 0.362 0.495 0.589 
BHA 0.860 0.910 1.101 1.289 
TBHQ 0.802 0.949 1.101 1.295 
AA 0.691 0.851 0.999 1.149 
 














4a 39.00 49.85 63.15 68.42 < 25 
4b 28.17 34.05 41.17 48.91 < 25 
4c 37.77 52.01 57.27 66.27 < 25 
5a 42.41 49.53 56.65 64.70 < 25 
5b 47.05 52.63 56.65 61.91 < 25 
5c 39.00 49.22 52.94 58.82 < 25 
6a 54.55 58.27 69.53 74.10 < 25 
6b 41.79 48.29 50.77 61.91 < 25 
6c 44.58 52.01 57.58 62.30 < 25 
BHA 63.46 68.11 69.65 72.13 < 25 
TBHQ 61.60 64.39 69.34 70.58 < 25 
AA. 63.15 65.63 70.58 72.44 < 25 




chlorine atom at C-5 position of indole system. 
Whereas, Rest of the compounds in the series 
exhibited moderate to less activity. 
Screening studies have demonstrated that the newly 
synthesized compounds have promising antibacterial 
and antifungal properties. Therefore, it was concluded 
that there exists better scope for further study on this 
class of compounds. 
aEC- Escherichia coli (MTCC-723), bSA- 
Staphylococcus aureus (ATCC-29513), cKP- Klebsiella 
pneumonia (NCTC-13368), dPA- Pseudomonas 
aeruginosa (MTCC-1688) eAO- Aspergillus oryzae 
(MTCC-3567T), fAN- Aspergillus niger (MTCC-281), 
gAF- Aspergillus flavus (MTCC-1973), hAT- 
Aspergillus terreus (MTCC-1782). 
 
Antitubercular activity 
The results of the antitubercular evaluation results are 
given in (Table V). Newly synthesized compounds (4-6) 
were assayed for inhibitory activity towards 
Mycobacterium tuberculosis H37Rv (ATCC2794). The 
minimum inhibitory concentration (MIC expressed as 
µg/mL) was determined for each compound. The 
compound 6a showed excellent activity against M. 
tuberculosis H37Rv (MIC= 3.125 µg/mL) than the 
standards Pyrazinamide and Streptomycin (MIC= 3.125 
and 6.25 µg/mL). Compounds 4a and 5a showed good 
activity against M. tuberculosis H37Rv (MIC= 6.25 
µg/mL). Compounds 4b and 5b showed moderate 
activity against M. tuberculosis H37Rv (MIC= 12.5 
µg/mL). In general, the brief structure–activity 
relationship (SAR) studies revealed that the presence of 
electron withdrawing group chlorine at C-5 indole 
system may be attributed for enhanced antitubercular 
activity in the series and has emerged as promising 






Materials and methods 
All the reagents were obtained commercially and 
used by further purification using standard procedures. 
Melting points were determined by an open capillary 
method and are uncorrected. Purity of the compounds 
was checked by thin layer chromatography using silica 
gel-G coated Al plates (Merck) and spots were 
visualized by exposing the dry plates in iodine vapors. 
The IR (KBr pellet) spectra were recorded on a Perkin-
Elmer (Spectrum ONE) FT-IR Spectrometer. The 1H 
and 13C NMR (DMSO-d6) spectra were recorded with a 
BRUKER NMR 500 and 125 MHz spectrometers, and 
the chemical shift values are expressed in ppm (δ scale) 
using tetramethylsilane as an internal standard. The 
mass spectral measurements were carried out by 
Electron Impact method on JEOL GC mate 
spectrometer at 70 eV. Elemental analyses were 
performed on flash EA 1112 series elemental analyzer.  
 
5-Substituted 2-phenyl-1H-indol-3-carboxaldehydes 
(2a-c) were prepared by literature method [36]. 
General procedure for the synthesis of ethyl 1, 
2-diamino-4-(5-substituted-2-phenyl-1H-indo-3-
yl)-5-cyano-6-oxo-1,6-dihydropyridin-3-
carboxylates (4a-c): mixture of compounds 1 (0.01 
mol), 2,5-disubstituted indol-3-carboxaldehyde (0.01 
mol) and ethyl-2-cyanoacetate (3) (0.01 mol) in 
ethanol (25mL) was refluxed for 5 h. The reaction 
mixture was cooled at room temperature and the solid 
obtained was filtered off, dried and crystallized to 
give compounds 4a-c, respectively (Scheme I).  
Ethyl 1, 2-diamino-4-(5-chloro-2-phenyl-1H-
indo-3-yl)-5-cyano-6-oxo-1,6-dihydropyridin-3-




(MIC µg/mL ) 
Antifungal activity 
(MIC µg/mL ) 
ECa SAb KPc PAd AOe ANf AFg ATh 
4a 62.5 125 125 125 125 62.5 125 250 
4b 250 250 250 250 500 500 250 500 
4c 125 500 500 500 500 250 125 500 
5a 125 125 250 62.5 125 62.5 250 250 
5b 500 250 500 250 250 125 250 500 
5c 125 500 250 250 250 500 250 500 
6a 125 62.5 250 62.5 125 125 125 125 
6b 500 250 500 250 500 250 500 500 
6c 250 500 500 250 250 125 250 500 
Gentamycin 125 125 250 125 -- -- -- -- 
Fluconazole -- -- -- -- 125 62.5 125 250 
 
Table V — Antitubercular activity of compounds (4-6) 

















carboxylate (4a): Yield: 72%; m.p. 220‐221ºC; Rf 
0.75 ethyl acetate: benzene (1:3) mixture; FT‐IR 
(KBr) (cm‐1): 3380 (NH2), 3289 (NH2), 3188 (NH), 
2198 (C≡N), 1771, 1684 (2 C=O), 1613 (C=C), 1568 
(C=N), 674 (C–Cl); 1H NMR (DMSO-d6): δ 2.49  
(t, J = 8.83Hz, 3H, CH3), 3.68 (q, J = 31.01 Hz, 2H, 
CH2CO), 5.77 and 8.77 (2s, 2H, 2NH), 7.62–8.38 (m, 
8H, Ar‐H), 11.10 (s, 1H, indole-NH); 13C NMR 
(DMSO-d6): δ 170.9, 166.6, 134.0, 132.8, 130.1, 
129.5, 128.3, 128.1, 127.8, 127.5, 126.8, 123.9, 122.7, 
121.5, 115.9, 114.5, 111.0, 89.5, 62.5 & 15.1; MS 
(EI) m/z 447 (M+), 449 (M++2); Anal. Calcd. for 
C23H18N5O3Cl (447.11): C, 61.68; H, 4.05; N, 15.64. 
Found: C, 61.71; H, 4.08; N, 15.71%. 
Ethyl 1, 2-diamino-4-(5-methyl-2-phenyl-1H-
indol)-5-cyano-6-oxo-1,6-dihydropyridin-3-
carboxylate (4b): Yield: 76%; m.p. 265‐266ºC; Rf 0.71 
ethyl acetate: benzene (1:3) mixture; FT‐IR (KBr) 
(cm‐1): 3388 (NH2), 3295 (NH2), 3187 (NH), 2197 
(C≡N), 1770, 1685 (2 C=O), 1617 C=C), 1570 (C=N); 
1H NMR (DMSO-d6): δ 1.39 (s, 1H, CH3), 2.50 (t, J = 
8.83Hz, 3H, CH3), 3.67 (q, J = 31.01 Hz, 2H, CH2CO), 
5.72 and 8.70 (2s, 2H, 2NH), 7.57–8.34 (m, 8H, Ar‐H), 
11.14 (s, 1H, indole-NH); MS (EI) m/z 427 (M+). Anal. 
Calcd. for C24H21N5O3 (427.16): C, 67.44; H, 4.95; N, 
16.38. Found: C, 67.41; H, 4.98; N, 16.51%. 
Ethyl 1, 2-diamino-4-(2-phenyl-1H-indol)-5-
cyano-6-oxo-1,6-dihydropyridin-3-carboxylate 
(4c): Yield: 76%; m.p. 24‐241ºC; Rf 0.82 ethyl 
acetate: benzene (1:4) mixture; FT‐IR (KBr) (cm‐1): 
3381 (NH2), 3292 (NH2), 3189 (NH), 2192 (C≡N), 
1769, 1680 (2 C=O), 1613 (C=C), 1568 (C=N); 1H 
NMR (DMSO-d6): 2.49 (t, J = 8.83Hz, 3H, CH3), 3.67 
(q, J = 31.01 Hz, 2H, CH2CO), 5.77 and 8.79 (2s, 2H, 
2NH), 7.64–8.39 (m, 9H, Ar‐H), 11.12 (s, 1H, indole-
NH); MS (EI) m/z 413 (M+). Anal. Calcd. for 
C23H19N5O3 (413.15): C, 66.82; H, 4.63; N, 16.94. 
Found: C, 66.88; H, 4.68; N, 16.91%. 
 
General procedure for the synthesis of ethyl 7-(5-
sunstituted-2-phenyl-1H-indo-3-yl)-5-cyano-6-oxo-
1,5-dihydro[1,2,4]triazol[1,5]pyridin-3-
carboxylates (5a-c):  
A mixture of compounds (4a-c) (0.01 mol) and 
triethyl orthoformate (0.02 mol) was refluxed for 3 h. 
The reaction mixture was cooled and the solid 
obtained was filtered off, dried and crystallized to 
give compounds 5a-c, respectively (Scheme I). 
Ethyl 7-(5-chloro-2-phenyl-1H-indo-3-yl)-5-
cyano-6-oxo-1,5-dihydro[1,2,4]triazol[1,5]pyridin-
3-carboxylate (5a): Yield: 65%; m.p. 187‐189ºC; Rf 
0.78 ethyl acetate: toluene (1:4) mixture; FT‐IR (KBr) 
(cm‐1): 3188 (NH), 3160 (NH), 2198 (C≡N), 1771, 
1684 (2 C=O), 1613 (C=C), 1568 (C=N), 674 (C–Cl); 
1H NMR (DMSO-d6): δ 2.50 (t, J = 8.81Hz, 3H, 
CH3), 3.66 (q, J = 31.03 Hz, 2H, CH2CO), 5.71 (s, 
1H, NH), 7.64–8.39 (m, 8H, Ar‐H), 11.12 (s, 1H, 
indole-NH); 13C NMR (DMSO-d6): δ 170.3, 166.2, 
160.8, 154.0, 135.3, 131.7, 129.8, 129.5, 127.8, 127.4, 
125.9, 123.6, 122.8, 121.5, 115.9, 114.4, 110.8, 90.1, 
63.3 & 15.2; MS (EI) m/z 457 (M+), 459 (M++2). 
Anal. Calcd. for C24H16N5O3Cl (457.09): C, 62.96; H, 
3.52; N, 15.30. Found: C, 62.98; H, 3.58; N, 15.38%. 
Ethyl 7-(5-methyl-2-phenyl-1H-indo-3-yl)-5-
cyano-6-oxo-1,5-dihydro[1,2,4]triazol[1,5] pyridin-
3-carboxylate (5b): Yield: 67 %; m.p. 171‐172ºC; Rf 
0.79 ethyl acetate: toluene (1:3) mixture; FT‐IR (KBr) 
(cm‐1): 3190 (NH), 3168 (NH), 2191 (C≡N), 1767, 
1680 (2 C=O), 1611 (C=C), 1565 (C=N); 1H NMR 
(DMSO-d6): δ 1.39 (s, 1H, CH3), 2.54 (t, J = 8.80Hz, 
3H, CH3), 3.68 (q, J = 31.04 Hz, 2H, CH2CO), 5.69 
(s, 1H, NH), 7.60–8.39 (m, 8H, Ar‐H), 11.14 (s, 1H, 
indole-NH); MS (EI) m/z 437 (M+). Anal. Calcd. for 
C25H19N5O3 (437.15): C, 68.64; H, 4.38; N, 16.01. 
Found: C, 68.68; H, 4.35; N, 16.14%. 
Ethyl 7-(2-phenyl-1H-indo-3-yl)-5-cyano-6-oxo-
1,5-dihydro[1,2,4]triazol[1,5]pyridin-3-carboxylate 
(5c): Yield: 69 %; m.p. 144‐145ºC; Rf 0.75 ethyl 
acetate: toluene (1:1) mixture; FT‐IR (KBr) (cm‐1): 3198 
(NH), 3172 (NH), 2164 (C≡N), 1769, 1677 (2 C=O), 
1613 (C=C), 1569 (C=N); 1H NMR (DMSO-d6): δ: 2.55 
(t, J = 8.80Hz, 3H, CH3), 3.67 (q, J = 31.04 Hz, 2H, 
CH2CO), 5.71 (s, 1H, NH), 7.59–8.41 (m, 9H, Ar‐H), 
11.17 (s, 1H, indole-NH); MS (EI) m/z 423 (M+). Anal. 
Calcd. for C24H17N5O3 (423.13): C, 68.08; H, 4.05;  
N, 16.54. Found: C, 68.10; H, 4.15; N, 16.60%. 
 
General procedure for the synthesis of ethyl 7-(5-
substituted-2-phenyl-1H-indo-3-yl)-5-cyano-6-oxo-
1,5-dihydro[1,2,4]triazol[1,5] pyridin-8-
carbohydrazides (6a-c):  
A mixture of compounds (5a-c) (0.01 mol) and 
hydrazine hydrate 98% (0.015 mol) in tetrahydrofuran 
(20 mL) was heated under reflux condition for 5 h and 
then allowed to cool. The Precipitate that formed was 
filtered off, dried and crystallized to give compounds 
6a-c, respectively (Scheme I). 
Ethyl 7-(5-chloro-2-phenyl-1H-indo-3-yl)-5-
cyano-6-oxo-1,5-dihydro[1,2,4]triazol[1,5] pyridin-
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The control contains FeCl2 and ferrozine, complex 
formation molecule. The results are shown in the 
(Table III). 
 
In-vitro antimicrobial activity 
The in vitro antimicrobial activity of all the 
synthesized compounds (4-6) was carried out by broth 
micro dilution method40 in DMF at concentration 500, 
250, 125 and 62.5 µg/mL. Muller hinton broth was 
used as nutrient medium to growth and dilutes the 
compound suspension for the test bacteria and 
Saboured Dextrose broth used for fungal nutrition. 
Inoculums size for test strain was adjusted to 108 CFU 
[Colony Forming Unit] per milliliter by comparing 
the turbidity. The strain employed for the activity was 
procured from Department of Biotechnolgy, Sahyadri 
Science College, Shivamoga. 
The compounds (4-6) were screened for their 
antibacterial activity against Escherichia coli (MTCC-
723), Staphylococcus aureus (ATCC-29513), 
Klebsiella pneumonia (NCTC-13368) and 
Pseudomonas aeruginosa (MTCC-1688), as well 
antifungal activity against Aspergillus oryzae 
(MTCC-3567T), Aspergillus niger (MTCC-281), 
Aspergillus flavus (MTCC-1973) and Aspergillus 
terreus (MTCC-1782). DMSO used as a vehicle to get 
desired concentration of compounds to test upon 
microbial strains. The lowest concentration which 
showed no visible growth after spot subculture was 
considered as MIC for each compound. The standard 
antibiotics used for comparison in present study were 
gentamycin for evaluating for antibacterial activity as 
well as and fluconazole for antifungal activity. The 
protocols are summarized in (Table IV). 
 
Antitubercular activity using Alamar Blue Dye 
The antitubercular activity of compounds (4-6) was 
assessed against M. tuberculosis H37RV strain using 
micro plate alamar blue dye assay (MABA)41. Briefly, 
200 µL of sterile deionzed water was added to all 
outer perimeter wells of sterile 96 wells plate to 
minimize evaporation of medium in the test wells 
during incubation. The 96 wells plate received 100 µL 
of the middle brook 7H9 broth and serial dilution of 
compounds was made directly on plate. The final drug 
concentrations tested were 100 to 0.2 µg/mL and 
compared with standards pyrazinamide 3.125 µg/mL 
and streptomycin 6.25 µg/mL. Plates were covered 
and sealed with parafilm and incubated at 37°C for 
five days. After this time, 25 µL freshly prepared 1:1 
mixture of almar blue reagent and 10 % tween-80 was 
added to the plate and incubated for 24 h. A blue 
color in the well was interpreted as no bacterial 
growth, and pink color was scored as growth. The 
MIC (Minimal inhibition concentration) was defined 
as lowest drug concentration which prevented the 
color change from blue to pink. The results are shown 
in the (Table V). 
 
Conclusions 
In summary, few novel indole derivatives were 
prepared, in moderate to high yields. Our antioxidant, 
antimicrobial and antitubercular activities results 
proved that the chlorine substituent is essential to 
exhibit better activity. The presence of chlorine 
electron-withdrawing group on the indole system 
mostly favors the activity. Screening studies have 
demonstrated that the newly synthesized compounds 
have promising antimicrobial and antitubercular 
properties. Therefore, it was concluded that there 
exists better scope for further study on this class of 
compounds. Based on these excellent results some of 
the compounds will be screened for anticancer 
activity which will be reported in due course. 
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